S&P 500   3,699.12 (+0.88%)
DOW   30,218.26 (+0.83%)
QQQ   305.52 (+0.41%)
AAPL   122.25 (-0.56%)
MSFT   214.36 (+0.06%)
FB   279.70 (-0.76%)
GOOGL   1,823.76 (+0.11%)
AMZN   3,162.58 (-0.76%)
TSLA   599.04 (+0.95%)
NVDA   542.33 (+1.21%)
BABA   267.25 (+0.13%)
CGC   28.59 (-0.14%)
GE   10.88 (+2.64%)
MU   73.34 (+4.92%)
AMD   94.04 (+1.87%)
T   29.54 (+1.06%)
NIO   43.04 (-5.09%)
F   9.34 (+1.41%)
ACB   10.89 (-3.11%)
BA   232.71 (-1.89%)
NFLX   498.31 (+0.16%)
GILD   61.56 (+1.15%)
DIS   154.14 (+0.59%)
S&P 500   3,699.12 (+0.88%)
DOW   30,218.26 (+0.83%)
QQQ   305.52 (+0.41%)
AAPL   122.25 (-0.56%)
MSFT   214.36 (+0.06%)
FB   279.70 (-0.76%)
GOOGL   1,823.76 (+0.11%)
AMZN   3,162.58 (-0.76%)
TSLA   599.04 (+0.95%)
NVDA   542.33 (+1.21%)
BABA   267.25 (+0.13%)
CGC   28.59 (-0.14%)
GE   10.88 (+2.64%)
MU   73.34 (+4.92%)
AMD   94.04 (+1.87%)
T   29.54 (+1.06%)
NIO   43.04 (-5.09%)
F   9.34 (+1.41%)
ACB   10.89 (-3.11%)
BA   232.71 (-1.89%)
NFLX   498.31 (+0.16%)
GILD   61.56 (+1.15%)
DIS   154.14 (+0.59%)
S&P 500   3,699.12 (+0.88%)
DOW   30,218.26 (+0.83%)
QQQ   305.52 (+0.41%)
AAPL   122.25 (-0.56%)
MSFT   214.36 (+0.06%)
FB   279.70 (-0.76%)
GOOGL   1,823.76 (+0.11%)
AMZN   3,162.58 (-0.76%)
TSLA   599.04 (+0.95%)
NVDA   542.33 (+1.21%)
BABA   267.25 (+0.13%)
CGC   28.59 (-0.14%)
GE   10.88 (+2.64%)
MU   73.34 (+4.92%)
AMD   94.04 (+1.87%)
T   29.54 (+1.06%)
NIO   43.04 (-5.09%)
F   9.34 (+1.41%)
ACB   10.89 (-3.11%)
BA   232.71 (-1.89%)
NFLX   498.31 (+0.16%)
GILD   61.56 (+1.15%)
DIS   154.14 (+0.59%)
S&P 500   3,699.12 (+0.88%)
DOW   30,218.26 (+0.83%)
QQQ   305.52 (+0.41%)
AAPL   122.25 (-0.56%)
MSFT   214.36 (+0.06%)
FB   279.70 (-0.76%)
GOOGL   1,823.76 (+0.11%)
AMZN   3,162.58 (-0.76%)
TSLA   599.04 (+0.95%)
NVDA   542.33 (+1.21%)
BABA   267.25 (+0.13%)
CGC   28.59 (-0.14%)
GE   10.88 (+2.64%)
MU   73.34 (+4.92%)
AMD   94.04 (+1.87%)
T   29.54 (+1.06%)
NIO   43.04 (-5.09%)
F   9.34 (+1.41%)
ACB   10.89 (-3.11%)
BA   232.71 (-1.89%)
NFLX   498.31 (+0.16%)
GILD   61.56 (+1.15%)
DIS   154.14 (+0.59%)
Log in
ASX:LCT

Living Cell Technologies Limited (LCT.AX) Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range
A$0.01
MA: A$0.01
A$0.01
52-Week Range N/A
Volume76,622 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Living Cell Technologies Limited, a biotechnology company, discovers, develops, and commercializes regenerative treatments that use naturally occurring cells to restore functions in New Zealand. The company's lead product is NTCELL, an alginate coated capsule, which is in clinical trials for the treatment of Parkinson's disease. It also develops LP-003, a peptide drug that reduces caloric intake targeting obesity; and LC-002, a novel calcitonin gene-related peptide antagonist targeting migraine. Living Cell Technologies Limited has a research collaboration agreement with the University of Auckland to identify products that utilize patented novel peptide synthetic chemistry technology for the treatments for obesity and migraine. The company was founded in 1987 and is based in Melbourne, Australia.

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.56 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone61 3 8689 9997
EmployeesN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$553,692.00
Book ValueA$0.01 per share

Profitability

Miscellaneous

Next Earnings DateN/A
OptionableNot Optionable

Receive LCT News and Ratings via Email

Sign-up to receive the latest news and ratings for LCT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Living Cell Technologies Limited (LCT.AX) (ASX:LCT) Frequently Asked Questions

What stocks does MarketBeat like better than Living Cell Technologies Limited (LCT.AX)?

Wall Street analysts have given Living Cell Technologies Limited (LCT.AX) a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Living Cell Technologies Limited (LCT.AX) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Living Cell Technologies Limited (LCT.AX)'s earnings last quarter?

Living Cell Technologies Limited (LCT.AX) (ASX:LCT) released its quarterly earnings results on Tuesday, February, 19th. The company reported $0.00 earnings per share for the quarter.
View Living Cell Technologies Limited (LCT.AX)'s earnings history
.

Who are some of Living Cell Technologies Limited (LCT.AX)'s key competitors?

What other stocks do shareholders of Living Cell Technologies Limited (LCT.AX) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Living Cell Technologies Limited (LCT.AX) investors own include eWellness Healthcare (EWLL), Energous (WATT), Cheniere Energy (LNG) and AllianceBernstein Global High Income Fund (AWF).

Who are Living Cell Technologies Limited (LCT.AX)'s key executives?

Living Cell Technologies Limited (LCT.AX)'s management team includes the following people:
  • Dr. Kenneth Taylor, CEO & Exec. Director (Age 77, Pay $357.3k)
  • Mr. Daya Uka, Chief Financial Officer
  • Dr. Janice Lam, Chief Operating Officer
  • Mr. Mark Andrew Licciardo B Bus (Acc), FCIS, GAICD, GradDip CSP, FGIA, Company Sec. (Age 56)

What is Living Cell Technologies Limited (LCT.AX)'s stock symbol?

Living Cell Technologies Limited (LCT.AX) trades on the ASX under the ticker symbol "LCT."

How big of a company is Living Cell Technologies Limited (LCT.AX)?

Living Cell Technologies Limited (LCT.AX) has a market capitalization of $0.00 and generates $553,692.00 in revenue each year.

What is Living Cell Technologies Limited (LCT.AX)'s official website?

The official website for Living Cell Technologies Limited (LCT.AX) is www.lctglobal.com.

How can I contact Living Cell Technologies Limited (LCT.AX)?

The company can be reached via phone at 61 3 8689 9997.

This page was last updated on 12/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.